Increased plasma thrombopoietin levels in patients with myelodysplastic syndrome: A reliable marker for a benign subset of bone marrow failure

Haematologica

Volumn 98, Issue 6, 2013, Pages 901-907

  Seiki, Yu ^a   Sasaki, Yumi ^a   Hosokawa, Kohei ^a   Saito, Chizuru ^a   Sugimori, Naomi ^a   Yamazaki, Hirohito ^a   Takami, Akiyoshi ^a   Nakao, Shinji ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CYCLOSPORIN A; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; THROMBOPOIETIN; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLONAL VARIATION; DRUG RESPONSE; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PREVALENCE; PROGNOSIS; PROGRESSION FREE SURVIVAL; RECEIVER OPERATING CHARACTERISTIC; REFRACTORY ANEMIA; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BLOOD CELLS; BONE MARROW; FEMALE; GPI-LINKED PROTEINS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; ROC CURVE; THROMBOCYTOPENIA; THROMBOPOIETIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84878018531     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.066217     Document Type: Article

References (33)

1. Sloand EM, Olnes MJ, Shenoy A, Weinstein B, Boss C, Loeliger K, et al. Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions. J Clin Oncol. 2010;28(35): 5166-73.
2. Wang H, Chuhjo T, Yasue S, Omine M, Nakao S. Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria-type cells in bone marrow failure syndrome. Blood. 2002;100(12):3897-902.
3. Ishikawa T, Tohyama K, Nakao S, Yoshida Y, Teramura M, Motoji T, et al. A prospective study of cyclosporine A treatment of patients with low-risk myelodysplastic syndrome: presence of CD55(-)CD59(-) blood cells predicts platelet response. Int J Hematol. 2007;86(2):150-7.
4. Kusumoto S, Jinnai I, Matsuda A, Murohashi I, Bessho M, Saito M, et al. Bone marrow patterns in patients with aplastic anaemia and myelodysplastic syndrome: observations with magnetic resonance imaging. Eur J Haematol. 1997;59(3):155-61.
5. Barrett J, Saunthararajah Y, Molldrem J. Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology? Semin Hematol. 2000;37(1):15-29.
6. Dunn DE, Tanawattanacharoen P, Boccuni P, Nagakura S, Green SW, Kirby MR, et al. Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes. Ann Intern Med. 1999;131(6):401-8.
7. Wang H, Chuhjo T, Yamazaki H, Shiobara S, Teramura M, Mizoguchi H, et al. Relative increase of granulocytes with a paroxysmal nocturnal haemoglobinuria phenotype in aplastic anaemia patients: the high prevalence at diagnosis. Eur J Haematol. 2001;66 (3):200-5.
8. Saunthararajah Y, Nakamura R, Wesley R, Wang QJ, Barrett AJ. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood. 2003;102(8):3025-7.
9. Sugimori C, Mochizuki K, Qi Z, Sugimori N, Ishiyama K, Kondo Y, et al. Origin and fate of blood cells deficient in glycosylphosphatidylinositol-anchored protein among patients with bone marrow failure. Br J Haematol. 2009;147(1):102-12.
10. Borowitz MJ, Craig FE, Digiuseppe JA, Illingworth AJ, Rosse W, Sutherland DR, et al. Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry. Cytometry B Clin Cytom. 2010;78(4): 211-30.
11. Emmons RV, Reid DM, Cohen RL, Meng G, Young NS, Dunbar CE, et al. Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood. 1996;87(10):4068-71.
12. Hou M, Andersson PO, Stockelberg D, Mellqvist UH, Ridell B, Wadenvik H. Plasma thrombopoietin levels in thrombocytopenic states: implication for a regulatory role of bone marrow megakaryocytes. Br J Haematol. 1998;101(3):420-4.
13. Ogata K, Tamura H. Thrombopoietin and myelodysplastic syndromes. Int J Hematol. 2000;72(2):173-7.
14. Tamura H, Ogata K, Luo S, Nakamura K, Yokose N, Dan K, et al. Plasma thrombopoietin (TPO) levels and expression of TPO receptor on platelets in patients with myelodysplastic syndromes. Br J Haematol. 1998;103(3):778-84.
15. Camitta BM, Doney K. Immunosuppressive therapy for aplastic anemia: indications, agents, mechanisms, and results. Am J Pediatr Hematol Oncol. 1990;12(4):411-24.
16. Parker C, Omine M, Richards S, Nishimura J, Bessler M, Ware R, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood. 2005;106(12):3699-709.
17. Kulagin A, Golubovskaya I, Ganapiev A, Babenko E, Sipol A, Pronkina N, et al. Prognostic value of minor PNH clones in aplastic anaemia patients treated with ATGbased immunosuppression: results of a twocentre prospective study. Bone Marrow Transplantation. 2011;46:S83-S4.
18. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108(2):419-25.
19. Ishiyama K, Chuhjo T, Wang H, Yachie A, Omine M, Nakao S. Polyclonal hematopoiesis maintained in patients with bone marrow failure harboring a minor population of paroxysmal nocturnal hemoglobinuria-type cells. Blood. 2003;102(4):1211-6.
20. Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007;25(23):3503-10.
21. Feng XM, Scheinberg P, Wu CO, Samsel L, Nunez O, Prince C, et al. Cytokine signature profiles in acquired aplastic anemia and myelodysplastic syndromes. Haematologica. 2011;96(4):602-6.
22. Malcovati L, Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005;23(30):7594-603.
23. Nosslinger T, Tuchler H, Germing U, Sperr WR, Krieger O, Haase D, et al. Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes. Ann Oncol. 2010;21(1):120-5.
24. Nagasawa T, Hasegawa Y, Shimizu S, Kawashima Y, Nishimura S, Suzukawa K, et al. Serum thrombopoietin level is mainly regulated by megakaryocyte mass rather than platelet mass in human subjects. Br J Haematol. 1998;101(2):242-4.
25. Kaushansky K. Thrombopoietin: the primary regulator of megakaryocyte and platelet production. Thromb Haemost. 1995;74(1):521-5.
26. Nagata Y, Shozaki Y, Nagahisa H, Nagasawa T, Abe T, Todokoro K. Serum thrombopoietin level is not regulated by transcription but by the total counts of both megakaryocytes and platelets during thrombocytopenia and thrombocytosis. Thromb Haemost. 1997;77(5):808-14.
27. de Sauvage FJ, Carver-Moore K, Luoh SM, Ryan A, Dowd M, Eaton DL, et al. Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin. J Exp Med. 1996;183(2):651-6.
28. Sugimori N, Kondo Y, Shibayama M, Omote M, Takami A, Sugimori C, et al. Aberrant increase in the immature platelet fraction in patients with myelodysplastic syndrome: a marker of karyotypic abnormalities associated with poor prognosis. Eur J Haematol. 2009;82(1):54-60.
29. Bacigalupo A, Broccia G, Corda G, Arcese W, Carotenuto M, Gallamini A, et al. Antilymphocyte globulin, cyclosporin, and granulocyte colony-stimulating factor in patients with acquired severe aplastic anemia (SAA): a pilot study of the EBMT SAA Working Party. Blood. 1995;85(5):1348-53.
30. Sugimori C, Yamazaki H, Feng X, Mochizuki K, Kondo Y, Takami A, et al. Roles of DRB1 *1501 and DRB1 *1502 in the pathogenesis of aplastic anemia. Exp Hematol. 2007;35(1):13-20.
31. Sugimori C, Chuhjo T, Feng XM, Yamazaki H, Takami A, Teramura M, et al. Minor population of CD55(-)CD59(-) blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia. Blood. 2006;107(4):1308-14.
32. Hosokawa K, Katagiri T, Sugimori N, Ishiyama K, Sasaki Y, Seiki Y, et al. Favorable outcome of patients who have 13q deletion: a suggestion for revision of the WHO 'MDSU' designation. Haematologica. 2012; 97(12):1845-9.
33. Greenberg PL, Attar E, Battiwalla M, Bennett JM, Bloomfield CD, DeCastro CM, et al. Myelodysplastic syndromes. J Natl Compr Canc Netw. 2008;6(9):902-26.